Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 7/20 | 0.49 |
| ▸ | FLT1 | P17948 | 5/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 6/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1940183 | 0.88 | KDR (0.49) | MAPTKMT2ACRHBPCRHR2KDR | |
| SCHEMBL1942113 | 0.88 | KDR (0.49) | MAPTKMT2ACRHBPCRHR2KDR | |
| SCHEMBL1942972 | 0.88 | KMT2A (0.53) | MAPTKMT2ACRHBPCRHR2KDR | |
| SCHEMBL3924396 | 0.87 | KDR (0.47) | MAPTKMT2ACRHBPCRHR2KDR | |
| SCHEMBL1940215 | 0.87 | KDR (0.54) | MAPTKMT2ACRHBPCRHR2KDR | |
| SCHEMBL3924985 | 0.87 | KDR (0.49) | MAPTKMT2ACRHBPCRHR2KDR | |
| SCHEMBL1941133 | 0.87 | MAPT (0.53) | MAPTKMT2ACRHBPCRHR2KDR | |
| SCHEMBL1941580 | 0.87 | KMT2A (0.48) | MAPTKMT2ACRHBPCRHR2KDR | |
| SCHEMBL3923956 | 0.86 | KDR (0.54) | MAPTKMT2ACRHBPCRHR2KDR | |
| SCHEMBL3924120 | 0.86 | KDR (0.52) | MAPTKMT2ACRHBPCRHR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544703-B2 | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | FLT4, FLT1, TIE1 | MAPT 4537/4885KMT2A 2966/4885CRHBP 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.